Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints

Biogen (BIIB) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of$3.42. Earnings rose 17% year over year on a reported basis, boosted by the company’s cost-cutting efforts.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Total revenues came in at $2.46 billion, up 3% year over year on a reported basis and 2% on a constant-currency basis. Lower sales of Biogen’s key multiple sclerosis (MS) drugs like Tecfidera and Tysabri ...